Prostate Cancer

News, Updates & Research

Follow Us: Facebook, Twitter & Youtube

Brachytherapy Beneficial in Low Risk Prostate Cancer

Low-dose-rate (LDR) brachytherapy with or without androgen deprivation therapy may be the optimal treatment option for men with T1c to T3a prostate cancer (PCa), according to a new retrospective study published in Oncology Letters. For full article click HERE.

Patient Survey on Impact of Prostate Cancer

Men who are diagnosed with prostate cancer at later stages of the disease are more likely to say that their disease has affected several aspects of their life, including their self-esteem, how they share feelings with others, and how they feel about their sexual...

Support the Foundation while you shop for the holidays

Black Friday and Cyber Monday are two of the busiest shopping days of the year. Support us when you shop on Amazon on Black Friday, Cyber Monday and the holiday season. Begin your Amazon shopping on this link: smile.amazon.com/ch/27-4434212 and Amazon donates to the...

Early diagnosis is key to surviving prostate cancer

Dr. Gregory Merrick says the key to surviving prostate cancer is to undergo screening for early prostate cancer detection.  That combined with a healthy lifestyle is key to men's health. You can read his whole interview here: "Early Diagnosis Remains Key to Surviving...

September is Prostate Cancer Awareness Month!

September is National Prostate Cancer Awareness Month. Did you know that one in six men will be diagnosed with prostate cancer during their lifetime.  It's important to talk to your family and friends about the risk of prostate cancer, and the importance of screening....

PCa Commentary

Expert Commentary On The Latest Prostate Cancer Topics

Written by Dr. Ed Weber

PCa Commentary is a well-researched, clearly presented commentary targeted to medical providers and others interested in current prostate cancer treatment. Each PCa Commentary edition offers an analysis of new developments in the field of prostate cancer with essays discussing and evaluating treatment management options for this disease.

PCaCommentary #148: ACTIVE SURVEILLANCE – What’s New.

Active surveillance (AS) is an increasingly recommended strategy for carefully selected men with a biopsy diagnosis of low grade, localized prostate cancer.  It involves delaying primary intervention with careful follow-up monitoring with a goal of avoiding...

PCa Commentary #147: Olaparib and Rucaparib (PARP inhibitors)

OLAPARIB and RUCAPARIB (PARP inhibitors): These newly FDA approved agents now offer a much needed additional treatment option for men with metastatic castration resistant prostate cancer (mCRPC). The prostate cancer field is abuzz with encouraging reports of efficacy...

PCa Commentary # 146: Radium-223 (Xofigo); A Radioisotope Treatment for Prostate Cancer Metastatic to Bone. The radiobiology of Radium-223 suggests greater effectiveness when used early in metastatic castration-resistant prostate cancer (mCRPC).

In 2013 Radium-223 was FDA approved for treatment of prostate cancer patients with bone metastases on the basis of a large randomized trial, ASYMPCA, comparing the radioisotope to a placebo. In 708 heavily pretreated men, the overall median survival was extended by...

UNDERSTANDING PROSTATE CANCER

Prostate Cancer

What is Prostate Cancer?

What is Prostate Cancer, the Symptoms, Risk Factors? What does the Prostate do, where is it located?

Prostate Cancer Tests and Diagnostics

Diagnosed with Prostate Cancer?

What tests confirm the presence of prostate cancer? Learn how doctors diagnose prostate cancer.

Prostate Cancer Treatments

Treating Prostate Cancer.

Patients have options when it comes to the prostate cancer treatments. Learn about your options.

Remission versus Recurrence?

Relapse of prostate cancer is way more common than you might think. Many men treated for prostate cancer have their cancer return, recurrence, which can lead to a lifetime of treatment. Recurrence is determined by periodic monitoring PSA Levels in the blood. Remaining in remission for 10-15 years after prostate cancer treatment, makes it very unlikely that the cancer will ever return. Complete remission, no more treatment. Prostate Cancer Free studies treatment outcomes. This information is available in a downloadable or printable study.

Get The Study

Help To Continue the Work!

The Prostate Cancer Free Foundation, reviews the results of hundreds of thousands of men treated for prostate cancer. Tracking them for years. This information is available to you, and others like you, to help find the best prostate cancer treatment. This work takes time, effort, resources all of it done by volunteers. Please help us continue. Please Donate!